For hereditary ATTR amyloidosis, small molecule stabilizer therapeutics and gene-silencing medications inhibit or potentially reverse neurologic deterioration; for patients with amyloid cardiomyopathy (ATTR or ATTRwt), tafamidis decreases all-cause mortality and cardiovascular-related hospitalizations.